Royalty advances – Vic Varney http://vicvarney.com/ Wed, 16 Jun 2021 01:39:33 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://vicvarney.com/wp-content/uploads/2021/06/cropped-icon-32x32.png Royalty advances – Vic Varney http://vicvarney.com/ 32 32 Sony Music Entertainment to Pay Royalties to Historic Artists in Landmark Decision https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-historic-artists-in-landmark-decision/ https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-historic-artists-in-landmark-decision/#respond Wed, 16 Jun 2021 00:15:32 +0000 https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-historic-artists-in-landmark-decision/ In a historic move in the industry, Sony Music Entertainment has announced that it will begin paying royalties to heritage artists who signed with the company before 2000 and have yet to recover their record advances. Dubbed the Legacy Unrecouped Balance program, the plan is a continuation of Sony’s Artists Forward initiative to improve industry […]]]>

In a historic move in the industry, Sony Music Entertainment has announced that it will begin paying royalties to heritage artists who signed with the company before 2000 and have yet to recover their record advances.

Dubbed the Legacy Unrecouped Balance program, the plan is a continuation of Sony’s Artists Forward initiative to improve industry practices and transparency among creatives, with Sony detailing the move in a letter to thousands of people. artists during the weekend.

Throughout the 20th century, many recording contracts were drafted in a way that negated the possibility for artists to earn catalog royalties in the event that they failed to recover their initial recording prepayments. .

Going forward, however, Sony will not account for unrecovered balances from skilled artists, songwriters, and producers who signed with the company before 2000 and have not yet recovered their advances.

As part of the policy, legacy laws will now begin collecting royalties on a regular basis, including payments backdated to January 1, 2021.

Eligible artists, producers and songwriters will be notified of their eligibility for the program in the coming weeks.

In a letter explaining the initiative, Sony Music Entertainment noted that the Legacy Unrecouped Balance program would not result in the modification of contracts, but would pay through existing unpaid balances to “increase the ability of those who qualify to receive more money. ‘money from the use of their music’.

“As part of our continued focus on developing new financial opportunities for creators, we will no longer apply existing unrecovered balances to artist and attendee income generated on or after January 1, 2021 for eligible artists and attendees. from all over the world who signed with EMS before year. 2000 and have not received an advance from the year 2000 ”, reads the letter.

“Through this program, we are not modifying existing contracts, but choosing to pay on existing unrecovered balances to increase the ability of those who qualify to receive more money from the use of their music.”

]]>
https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-historic-artists-in-landmark-decision/feed/ 0
What’s new on acne and rosacea for 2021? https://vicvarney.com/whats-new-on-acne-and-rosacea-for-2021/ https://vicvarney.com/whats-new-on-acne-and-rosacea-for-2021/#respond Tue, 15 Jun 2021 04:07:47 +0000 https://vicvarney.com/whats-new-on-acne-and-rosacea-for-2021/ At the Symposium for Cosmetic Advances and Laser Education (SCALE) Acne and Rosacea Update, Emmy Graber, MD, Certified Dermatologist and Founder of the Dermatology Institute of Boston, and Affiliate Clinical Instructor, Northeastern University, Boston, Massachusetts presented further updates on the treatment of these conditions.1 The update included sarecycline as a potential treatment for rosacea. Sarecycline […]]]>

At the Symposium for Cosmetic Advances and Laser Education (SCALE) Acne and Rosacea Update, Emmy Graber, MD, Certified Dermatologist and Founder of the Dermatology Institute of Boston, and Affiliate Clinical Instructor, Northeastern University, Boston, Massachusetts presented further updates on the treatment of these conditions.1

The update included sarecycline as a potential treatment for rosacea. Sarecycline is already approved by the FDA for acne, but it is a new treatment for rosacea.2 The objective of the prospective, parallel-group, investigator-blind, pilot study of oral sarecycline was to examine its efficacy and safety in adults with moderate to severe papulopustular rosacea. .

There were 102 patients included in the study, 72 of these patients being treated with oral sarecycline and 25 with placebo. Primary outcomes included the percentage of patients with an Investigator’s Overall Assessment Score (IGA) of 0 or 1 (clear or almost clear) at week 12 and reduction in inflammatory lesions.

The secondary endpoints were a percentage of patients with IGA scores of 0 or 1 at weeks 4 and 8, a percentage reduction in inflammatory lesions at weeks 4 and 8, and an overall subject assessment (GAS) at each visit. The researchers also looked for adverse events (AEs) and local signs and symptoms on the skin.

At weeks 4, 8, and 12, sarecycline outperformed placebo in the percentage of patients with IGA 0/1. At week 12, 75% of patients had IGA scores 0/1 in the sarecycline arm vs. 16% in the placebo arm.

For the AEs, all were resolved except for one mild case of nausea and a headache at the end of the study.

For acne updates, a retrospective study of oral spironolactone (Aldactone; Pfizer) evaluated 403 adult patients with acne.3

The results of the study suggest that spironolactone maintains its effectiveness even with long-term use. In addition, 23% of the stops were due to AEs, of which 6 were related to menstrual problems, and the remaining 15 were due to symptoms such as dizziness, headache, frequent urination, fatigue, dry skin, anxiety and pain. abdominal.

There was also an update on isotretinoin dosing.4 There was a retrospective review of patients reviewing 1 or 2 courses of isotretinoin. Patients who received 2 courses tended to have a lower cumulative dose and shorter isotretinoin treatment duration after the acne cleared.

According to Graber, this suggests that a cumulative dose and the length of treatment after clearance are strong predictors of acne relapse. The study authors recommended treating up to the peak dose of 120 to 150 mg / kg for 6 months and prolonging treatment for 1 to 2 months.

The full SCALE conference will take place in Nashville, Tennessee, August 18-22.

Reference:

1. Gold M, Graber E, Sawyer, T. Webinar IMPROVING Your Practice: Update on Acne and Rosacea. Presented at: Acne and Rosacea Update; June 9, 2021.

2. Rosso JQ, Draelos ZD, Effron C, Kircik LH. Oral sarecycline for the treatment of papulopustular rosacea: results of a pilot efficacy and safety study. J Drugs Dermatol. 2021; 20 (4): 426-431. doi: 10.36849 / JDD.2021.5923

3. Garg V, Choi JK, James WD, Barbieri JS. Long-term use of spironolactone for acne in women: a case series of 403 patients. Journal of the American Academy of Dermatology. 2021; 84 (5): 1348-1355. doi: 10.1016 / j.jaad.2020.12.071

4. Tran PT, Berman HS, Leavitt E, Hogeling M, Cheng CE. Analysis of factors associated with relapse in patients on their second course of isotretinoin for acne vulgaris. J Am Acad Dermatol. 2021; 84 (3): 856-859. doi: 10.1016 / j.jaad.200.10.030

Disclosure:

E. Graber, MD has received research grants / support from Sebacia, Ortho Dermatologics, Hovione, consulting fees from SolGel, Verrica, Sebacia, Hovione, Almirall, Digital Diagnostics, part of the speakers bureau for Almirall, and royalty holder for Walter Kluwer Health.

]]>
https://vicvarney.com/whats-new-on-acne-and-rosacea-for-2021/feed/ 0
Sony Music Entertainment to pay royalties to unrecovered legacy artists to help clear anticipated debts https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-unrecovered-legacy-artists-to-help-clear-anticipated-debts/ https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-unrecovered-legacy-artists-to-help-clear-anticipated-debts/#respond Mon, 14 Jun 2021 21:58:00 +0000 https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-unrecovered-legacy-artists-to-help-clear-anticipated-debts/ Sony Music Entertainment has announced that it will begin paying royalties to historic artists and producers who signed with the company before 2000, and have yet to recover their record advances, Music trade around the world reports. The announcement was made in a letter the company sent to thousands of artists at the end of […]]]>

Sony Music Entertainment has announced that it will begin paying royalties to historic artists and producers who signed with the company before 2000, and have yet to recover their record advances, Music trade around the world reports.

The announcement was made in a letter the company sent to thousands of artists at the end of last week. The policy, dubbed the “Legacy Unrecouped Balance Program”, is part of a new Sony initiative called “Artists Forward”, which would focus on improving communication and transparency with creators.

Many older agreements and record breakthroughs, especially those signed before 2000, were made on terms that did not favor creators and made it particularly difficult for creators to secure royalties decades after the initial agreements were made. Sony’s new policy would be a first among major labels in the music industry.

While the new terms will not erase uncollected debts, they will “pay off existing uncollected balances to increase the ability of those who qualify to receive more money from the use of their music.”

The policy will retroactively impact royalty income from January 1, 2021. According to Sony, affected artists, producers and other creators will be notified of their eligibility for the Legacy Unrecouped Balance program in the coming weeks.

Review DJ Mag’s 2019 long read on how producers lose millions in royalties every year, here.

]]>
https://vicvarney.com/sony-music-entertainment-to-pay-royalties-to-unrecovered-legacy-artists-to-help-clear-anticipated-debts/feed/ 0
Qualcomm ready to invest in Arm if $ 40 billion deal with Nvidia collapses https://vicvarney.com/qualcomm-ready-to-invest-in-arm-if-40-billion-deal-with-nvidia-collapses/ https://vicvarney.com/qualcomm-ready-to-invest-in-arm-if-40-billion-deal-with-nvidia-collapses/#respond Sun, 13 Jun 2021 16:00:00 +0000 https://vicvarney.com/qualcomm-ready-to-invest-in-arm-if-40-billion-deal-with-nvidia-collapses/ US tech giant Qualcomm has opened the door to competing investment in Arm if the UK microchip company’s $ 40 billion (£ 28 billion) sale to Nvidia is blocked. Cristiano Amon, the new CEO of Qualcomm, said The telegraph he would be willing to buy a stake in Arm alongside a consortium of industry players […]]]>

US tech giant Qualcomm has opened the door to competing investment in Arm if the UK microchip company’s $ 40 billion (£ 28 billion) sale to Nvidia is blocked.

Cristiano Amon, the new CEO of Qualcomm, said The telegraph he would be willing to buy a stake in Arm alongside a consortium of industry players if owner SoftBank launched the company instead of selling it to Nvidia.

Nvidia hit back at the suggestion, saying an IPO would hamper Arm’s development.

Qualcomm and companies such as Google and Microsoft have raised concerns over Nvidia’s purchase of Arm, saying the deal threatens the independence of the Cambridge-based company and will hurt competition.

“If Arm has an independent future, I think you will find that many companies in the ecosystem, including Qualcomm, are very interested in investing in Arm,” Mr. Amon said.

“If it leaves SoftBank and enters a process to become a publicly traded company, [with] a consortium of companies investing, including many of its clients, I think those are great opportunities, ”he said.

“We will certainly be open to it and we have had discussions with other companies who feel the same way.” Industry sources said other companies who expressed concerns about the deal included Tesla and Amazon.

Arm, whose chip designs power billions of smartphones as well as a growing number of cars and connected smart devices, was listed in London until 2016, when SoftBank paid £ 24 billion for the company. .

Last September, Nvidia announced a deal to buy the company, although the deal is the subject of several competition investigations in the UK, US, EU and China.

Nvidia, which says it expects the acquisition to be completed early next year, has pledged to maintain Arm’s neutral licensing model, but opponents say the deal would give Nvidia a unprecedented position in areas such as data center chips.

“This is why it is a logical conclusion for us, and for many other companies, that investing in a strong, independent arm is probably the best for everyone,” said Amon.

A spokesperson for Nvidia said, “To grow and meet the demands of the AI ​​age, Arm needs more than an IPO. Arm needs an infusion of new technology that it can deliver to Arm licensees everywhere, which is why we have stepped up and agreed to purchase Arm. Our technologies and Qualcomm’s are highly complementary – we would love to help Qualcomm create new technologies and products for the entire Arm ecosystem. “

Nvidia recently filed the agreement with Chinese regulators to seek approval from Beijing authorities. The US Federal Trade Commission has asked corporate clients to respond to the deal, while the UK Competition and Markets Authority is assessing the acquisition on national security grounds.

Microsoft and Google declined to comment.

Read on for our full interview with Qualcomm’s new CEO Cristiano Amon

A handful of companies are credited with creating the modern smartphone industry. Apple, via its iPhone; Samsung, which brought cheaper devices to users around the world; and Google, whose Android software powered them.

Another entry on this list, but perhaps less well known, is Qualcomm. The $ 150 billion (£ 106 billion) titan of San Diego may not be a household name, but he has developed much of the technology behind the high-speed wireless networks that provide internet connections. 3G and 4G.

Bosses are now betting big on a 5G revolution – hoping for a massive acceleration in growth as the potential of high-speed internet technology extends from mobiles to almost every device in the modern home.

5G promises internet speeds up to 100 times faster than 4G networks, with more reliable connections. Technology has its share of skeptics who argue that the returns from such advances are marginal and that 5G has yet to demonstrate a compelling use case. Unsurprisingly, Qualcomm’s new chief executive, Cristiano Amon, is not one of them.

“When Qualcomm started developing 4G, everyone already had a phone,” he says.

]]>
https://vicvarney.com/qualcomm-ready-to-invest-in-arm-if-40-billion-deal-with-nvidia-collapses/feed/ 0
Steel Authority of India – Headwinds Building – ICICI Securities https://vicvarney.com/steel-authority-of-india-headwinds-building-icici-securities/ https://vicvarney.com/steel-authority-of-india-headwinds-building-icici-securities/#respond Sat, 12 Jun 2021 06:23:12 +0000 https://vicvarney.com/steel-authority-of-india-headwinds-building-icici-securities/ Steel Authority of India (SAIL) reported EBITDA lower than expected at Rs 61.5 billion. Even after adjusting for the salary revision provision (long term) from April 1, 2020, EBITDA is below estimates. This also leads to an increase in the salary cost estimates for the years 22 / 23E. The dividend for FY21 is also […]]]>

Steel Authority of India (SAIL) reported EBITDA lower than expected at Rs 61.5 billion. Even after adjusting for the salary revision provision (long term) from April 1, 2020, EBITDA is below estimates. This also leads to an increase in the salary cost estimates for the years 22 / 23E. The dividend for FY21 is also below expectations at Rs 2.8 / share. The investment thesis continues to face the double headwind of i) higher labor costs and ii) the possibility of higher investments. Coupled with peak spreads and most expectations of deleveraging in price, the investment thesis looks clouded. The pace of deleveraging, as investment programs will take time to ramp up, limits downside risks to some extent, unlike previous cycles. We move to SELL with an unchanged target of Rs 99 / share.

– Double headwinds of higher labor costs and higher investments, at peak spreads. Employee salary revisions are due, and approximately Rs 11.5 billion has been provided on an estimated basis in Q4FY21 (provided for the last four quarters). While more clarity will be achieved when calling after the results (scheduled for 11:00 am IST today), higher profits will lead to higher personnel costs. In addition, the media reported an increase in SAIL’s steel investments to bring steel capacity to 50 mtpa, in line with the company’s “Vision 2030” program. The double headwinds and peak spreads do not allow any constructive thesis on the name.

– Significant reduction in net debt. The net debt (excluding capital advances) was reduced from ~ Rs 161 billion to Rs 353 billion during fiscal year 21. If a controlled investment path is followed, SAIL has the option of reducing the net debt over the period. ‘EBITDA at 0.7x and 0.37x by FY22 / 23E. The significant prospects for deleveraging can only materialize and profits sustain if capital discipline is observed.

– Downgrade to SELL with a target of Rs99 / share (unchanged): Notwithstanding the current earnings scenario, we continue to attribute ~ 0.55x P / N to FY23E. We believe the FY22E volume assumptions are also at risk given a low T1FY22. In addition, given the peaks in spreads and the now long 5-quarter cycle, caution is in order.

– Risks upwards and downwards. It is still not clear whether the impact of royalties on the sale of captive iron ore can deliver the same level of profitability as previously anticipated. Steel sales volume is expected to reach 17-18mn in fiscal year 22E. However, a weak T1FY22 may lead to an elongation of the lens. In addition, a higher long product mix in Bhilai, Durgapur and IISCO may lead to underperformance of margins (due to diverging apartment and long prices) in the medium term.

Change in earnings and valuations

We have adjusted our profits to take into account the increase in labor costs and the diverging trend observed in the prices of flat and long products. FY 23E also saw a higher steel price and EBITDA assumption as we factored in an additional 2-3 quarters time in the steel cycle.

We are moving to the SELL rating with a price target of Rs99 / share (unchanged). We rate the company at 0.55x P / N (unchanged) based on FY23E.

Main upside and downside risks

The main downside risks are i) the cycle corrects itself ii) the announcement of an increase in organic investments. The main upside risks are i) higher iron ore sales to continue to generate additional EBITDA ii) better than expected deleveraging in fiscal years 21-23E.

Shares of STEEL AUTHORITY OF INDIA LTD. was last trading on BSE at Rs 135.05 from the previous close of Rs. 128.55. The total number of shares traded during the day was 9,222,362 in more than 43,552 trades.

The share hit an intraday high of Rs. 135.7 and an intraday low of 129.45. The net turnover during the day was Rs. 122,047,105.

]]>
https://vicvarney.com/steel-authority-of-india-headwinds-building-icici-securities/feed/ 0
Less travel, a lot of royalties for judges in 2020 https://vicvarney.com/less-travel-a-lot-of-royalties-for-judges-in-2020/ https://vicvarney.com/less-travel-a-lot-of-royalties-for-judges-in-2020/#respond Fri, 11 Jun 2021 21:33:54 +0000 https://vicvarney.com/less-travel-a-lot-of-royalties-for-judges-in-2020/ SCOTUS news By Amy Howe June 11, 2021 at 17:33 Fred Schilling, United States Supreme Court Collection The effects of the COVID-19 pandemic were reflected in an unusual source: the 2020 Judges’ Financial Disclosures, which the U.S. Courts Administrative Office released (and Fix the Court posted online) Friday. Unlike in previous years, judges mostly stayed […]]]>
SCOTUS news

Fred Schilling, United States Supreme Court Collection

The effects of the COVID-19 pandemic were reflected in an unusual source: the 2020 Judges’ Financial Disclosures, which the U.S. Courts Administrative Office released (and Fix the Court posted online) Friday. Unlike in previous years, judges mostly stayed close to home, with just two judges declaring reimbursements for travel after the pandemic in mid-March.

The financial information, which is published each year at this time, is relatively opaque. For example, they only show the value of investments in a wide range, and they don’t include the value of judges’ houses. However, the disclosures have also shed light on the groups the judges reach out to, their work outside of court, and even the gifts they receive.

Eight of the judges’ nine disclosures were made public on Friday. Judge Samuel Alito’s disclosure report was not included.

Two judges – Chief Justice John Roberts and Judge Sonia Sotomayor – did not declare any travel for which they were reimbursed. Four of their colleagues traveled only before the pandemic took hold. Justice Clarence Thomas traveled to Florida to speak at the University of Florida and the Florida chapter of the Federalist Society conservative legal group. Judge Stephen Breyer traveled to New York in January 2020 as part of his jury work for the prestigious Pritzker Architecture Prize, while Judge Elena Kagan also traveled to New York in late January to speak at the state bar. Unlike his colleagues, two of the trips reported by the court’s most recent judge, Amy Coney Barrett, involved a trip to Washington, DC, while serving as a judge at the Federal Court of Appeals in Indiana: Barrett came to Washington in January to judge a moot court competition at George Washington University and returned to February to serve as judge at the company’s Shakespeare Theater mock trial of peter pan.

Judge Neil Gorsuch made two trips before the pandemic hit – first to her home state of Colorado in February for the Federalist Society, and then in mid-March to speak at Ave Maria Law School in Naples, in Florida. Gorsuch also said he was reimbursed for a 12-day stay in Williamsburg, Va., In June for the George Mason University National Security Institute. Gorsuch reported income of $ 25,000.08 as an assistant professor to George Mason.

And as part of his work as a visiting professor at George Mason’s Antonin Scalia Law School (for which he was also awarded $ 25,000.08), Judge Brett Kavanaugh said he taught a two-credit course at the Supreme Court from Aug. 8-15. He said he was reimbursed by law school for accommodation and meals at an unspecified location in Farmington, Pa., During this time. Farmington is home to luxury Némacolin seaside resort and the Historic Summit Inn, an upscale hotel on top of a mountain.

Sotomayor and Gorsuch reported healthy outside income from advances on books and royalties. Sotomayor has several books to his credit, including his 2013 memoir My beloved world and books for college students and young children, which last year earned him $ 212,181 in advances and royalties – just short of his salary of $ 265,600. Gorsuch brought in $ 623.92 in royalties from Princeton University Press, presumably from his 2009 book on Assisted Suicide and Euthanasia, as well as $ 100,000 in royalties from Penguin Random House for his recent book, A republic, if you can keep it.

Several judges reported on external income from real estate. Breyer owns a vacation home in the Caribbean (where he was stolen by a man wielding a machete in 2012) which earned him between $ 15,001 and $ 50,000 in rental income, while Sotomayor reported between $ 5,001 and $ 15,000 in rental income for his New York apartment. Roberts and Kagan had less lucrative real estate: Roberts reported income from a cottage share in County Limerick, Ireland that was $ 1,000 or less, while Kagan reported between 1,001 and $ 2,500 in income from rental property in Washington.

Beyond their teaching posts, judges have held various non-judicial posts. In addition to his role as a Pritzker juror, Breyer was also an honorary administrator of the Dana-Farber Cancer Institute, where his wife, Joanna, worked as a psychologist. Gorsuch (along with Justice Anthony Kennedy, who retired in 2018) served on the board of Colonial Williamsburg and as honorary chairman of the National Constitution Center. And Kavanaugh continued his commitment to youth sports, as a coach of a youth basketball team and as an advisor to a sports advisory board of the Catholic Youth Organization. .

Earlier this year, Senator Sheldon Whitehouse, DR.I., and Senator Lindsey Graham, RS.C., called the judges disclose more information about gifts and outside income they receive. While 2020 has been a relatively quiet year for travel and gifts for judges, those calls are expected to continue as judges – all of whom are now fully vaccinated – return to normal activities in 2021.

This article was originally published by Howe on the Court.

]]>
https://vicvarney.com/less-travel-a-lot-of-royalties-for-judges-in-2020/feed/ 0
Sony Music to pay royalties to unrecovered legacy artists and producers amid major policy change https://vicvarney.com/sony-music-to-pay-royalties-to-unrecovered-legacy-artists-and-producers-amid-major-policy-change/ https://vicvarney.com/sony-music-to-pay-royalties-to-unrecovered-legacy-artists-and-producers-amid-major-policy-change/#respond Fri, 11 Jun 2021 15:32:46 +0000 https://vicvarney.com/sony-music-to-pay-royalties-to-unrecovered-legacy-artists-and-producers-amid-major-policy-change/ Sony Music Entertainment has announced that it will begin paying royalties to historical artists and producers who signed with the company before 2000 and who have yet to collect their record advances, Music trade around the world reports. Sony reportedly made the announcement in a letter the company sent to thousands of artists today; the […]]]>

Sony Music Entertainment has announced that it will begin paying royalties to historical artists and producers who signed with the company before 2000 and who have yet to collect their record advances, Music trade around the world reports. Sony reportedly made the announcement in a letter the company sent to thousands of artists today; the new policy, dubbed the “Legacy Unrecouped Balance Program”, is part of a new Sony initiative called “Artists Forward”, aimed at improving communication and transparency with creators.

The nature of record deals and record breakthroughs – especially contracts signed in the 20th century – has made it not uncommon for artists to be unable to earn royalties decades after first signing their contracts. . MBW reports that Sony’s new policy – a first among the majors – does not erase unrecovered debt, but “will pay off existing unrecovered balances to increase the ability of those who qualify to receive more money from the bank. use of their music. “

The policy will retroactively impact royalty income from January 1, 2021. According to Sony, artists, producers and other qualified participants will be notified of their eligibility for the Legacy Unrecouped Balance program in the coming weeks.

As streaming has reshaped the way music fans consume music and how royalties are generated, many players in the music industry have called on the biggest labels to institute policies similar to “Legacy Unrecouped.” Balance Program ”.

Beggars Group — the independent label group that includes 4AD, Matador, XL and others—wipe all outstanding debts on artist advances 15 years after an artist’s last contractual album. Beggars founder Martin Mills called on majors to put such a policy in place during a speech in 2016.

Read “Amid a racial justice calculation, pioneers of rap, reggae and R&B recount their struggles to get paid” from the field.

]]>
https://vicvarney.com/sony-music-to-pay-royalties-to-unrecovered-legacy-artists-and-producers-amid-major-policy-change/feed/ 0
Judy Murray can’t wait to see young contender challenge tennis royalty in Roland Garros final https://vicvarney.com/judy-murray-cant-wait-to-see-young-contender-challenge-tennis-royalty-in-roland-garros-final/ https://vicvarney.com/judy-murray-cant-wait-to-see-young-contender-challenge-tennis-royalty-in-roland-garros-final/#respond Fri, 11 Jun 2021 04:00:00 +0000 https://vicvarney.com/judy-murray-cant-wait-to-see-young-contender-challenge-tennis-royalty-in-roland-garros-final/ Whatever men triumph today in the singles semifinals at Roland Garros, the stage will be set for an exciting final. In one half of the range, veterans Rafael Nadal and Novak Djokovic will compete for a place in Sunday’s showpiece while in the other, newcomers Alexander Zverev and Stefanos Tsitsipas will face each other for […]]]>

Whatever men triumph today in the singles semifinals at Roland Garros, the stage will be set for an exciting final. In one half of the range, veterans Rafael Nadal and Novak Djokovic will compete for a place in Sunday’s showpiece while in the other, newcomers Alexander Zverev and Stefanos Tsitsipas will face each other for a chance to win a first Grand Slam title.

Whoever wins this afternoon’s semi-finals, we know the final will be compelling as the next generation of tennis stars attempt to reshuffle the current crop that has been around for so long. Whether it’s Nadal or Djokovic, Zverev or Tsitsipas, the challenge remains the same.

Judy Murray can’t wait to get in on the action and see if a young contender can steal the crown at the helm of tennis royalty. And the fact that Nadal and Djokovic are still competing at the highest level of the sport, she insists, will work both for and against them. On the one hand, their longevity is a source of inspiration for young players who are embarking on a career in tennis. On the other hand, it inevitably invites a challenge.

“It’s interesting how the draw went,” said Judy Murray ahead of the Cinch Championships in Queens. “What’s remarkable is that you have Djokovic and Nadal, who have won so many slams between them for so many years, still strong and playing great tennis.

“They are both so motivated and passionate in everything they do and they are the best example for young players to follow.

“They show the possibility of increasing the longevity of your career. So many advancements in sports science and sports medicine over the years prove that players can stay on top of a very grueling, individual sport with a stacked schedule. They play 11 months a year and continue to produce five incredible and epic sets over the course of a fortnight.

READ MORE: Jamie Murray attacks French federation over treatment of doubles players

“It’s just amazing. I’ve known Novak and Rafa since they were both about 11 years old – Jamie and Andy both played them in under-12 competitions in Europe – so they’re part of our furniture. I love that they’re there, doing great things, and inspiring everyone.

Djokovic and Federer – the world No.1 and No.3 respectively – may well be an inspiration with their tirelessness, but Murray believes their Grand Slam dominance will push Tsitsipas and Zverev to match their achievements.

She added: “On the other side of the board with Tsitsipas and Zverev, you have the young goalkeeper playing his own exciting brands of tennis; a lot of power, a lot of cunning. They are great athletes and they represent the future. They’re coming for these older guys.

“It’s a fascinating game because anyway you’re going to get a final between the old guard and one of the emerging players. In the top half you have the two guys with heaps of Grand Slam tournaments between them against Tsitsipas and Zverev who don’t. These are the young suitors who face the kings of the castle.

“I hate when people say they have no idea who is going to win – of course not, nobody knows! It will be a fascinating semi-finals and you will get that contrast in the final between the old guard and the next generation. So there is much to look forward to.

Judy Murray was speaking before the cinch championships. cinch is the main partner of the LTA, for more information, visit cinch.co.uk.

]]>
https://vicvarney.com/judy-murray-cant-wait-to-see-young-contender-challenge-tennis-royalty-in-roland-garros-final/feed/ 0
Official Rules for the Pain Management Funding Opportunity https://vicvarney.com/official-rules-for-the-pain-management-funding-opportunity/ https://vicvarney.com/official-rules-for-the-pain-management-funding-opportunity/#respond Tue, 08 Jun 2021 19:39:00 +0000 https://vicvarney.com/official-rules-for-the-pain-management-funding-opportunity/ 15. DISCLAIMER AND LIMITATIONS OF LIABILITY: By participating in the Funding Opportunity, each Participant agrees to hold harmless and hold harmless, to the maximum extent permitted by applicable law, the Sponsor, all Entities related to the Sponsor and the R&I of and against any claim or cause. action arising out of participation in the Funding […]]]>

15. DISCLAIMER AND LIMITATIONS OF LIABILITY: By participating in the Funding Opportunity, each Participant agrees to hold harmless and hold harmless, to the maximum extent permitted by applicable law, the Sponsor, all Entities related to the Sponsor and the R&I of and against any claim or cause. action arising out of participation in the Funding Opportunity or the receipt or use of any scholarship, including, but not limited to: (a) unauthorized human intervention in the Funding Opportunity; (b) the processing or evaluation of applications and / or presentations (c) technical errors related to computers, servers, suppliers or telephone or network lines; (d) printing errors; (e) lost, late, postage-paid, misdirected or undeliverable mail; (f) errors in the administration of the funding opportunity or the processing of entries; (g) injury or damage to persons or property which may be caused, directly or indirectly, in whole or in part, by the participation of each Investigation Team in the Funding Opportunity or the receipt of a Prize; (h) other errors or problems of any kind, whether mechanical, human, technical, network or electronic, or errors that may arise in the administration of the Funding Opportunity; (i) any Submission or other material uploaded or provided by a Participant that infringes the property rights of third parties, intellectual property rights, personal or moral rights or any other right, including, without limitation, the rights copyright, trademarks, patents, trade secrets, confidentiality, publicity or confidentiality obligations, or defames any person; (j) any failure by such participant to comply with these Official Rules or any applicable laws or regulations; (k) claims filed by any person or entities other than parties to these Official Rules arising out of or relating to such participant’s participation in the Funding Opportunity; or (l) the award or announcement of winners or finalists or in any other material related to the funding opportunity. Each Participant waives the right to claim any damages whatsoever, including, but not limited to, punitive, consequential, direct or indirect damages. Each Entrant further agrees to defend, indemnify and hold the Sponsor, all Sponsor’s related entities and R&I harmless from and against all third party claims or causes of action arising out of or related in any way. whether to the product or to that participant’s research, if any, and parties’ use thereof as permitted herein, including, without limitation, any claims for infringement of intellectual property rights .

THE SPONSOR SHALL NOT BE LIABLE TO ANY PARTICIPANT FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES IN CONNECTION WITH THE FUNDING OPPORTUNITY OR THIS AGREEMENT. EACH PARTICIPANT RELEASES AND AGREES TO INDEMNIFY AND HOLD THE SPONSOR AND ITS EMPLOYEES, OFFICERS, AFFILIATES, RELATED PARTIES, REPRESENTATIVES, AGENTS, PARTNERS, JUDGES AND ADVERTISING AND PROMOTION AGENCIES FROM ALL LIABILITY, INJURY, OR INJURY ANY KIND (INCLUDING ACTUAL LEGAL COSTS AND EXPENSES), KNOWN OR UNKNOWN, ABSOLUTE OR POTENTIAL, NOW OR IN THE FUTURE, RESULTING FROM OR RELATED TO: (1) HIS OR HIS OR HIS (IF APPLICABLE) FAILURE TO SEEK COMPLY WITH ANY OF THE TERMS OF THIS AGREEMENT OR OTHER APPLICABLE RULES; (2) ANY FALSE REPRESENTATION THAT HE, SHE OR SHE (IF ANY) MAKES TO THE SPONSOR UNDER THIS AGREEMENT OR OTHERWISE; (3) SA, IT OR ITS PARTICIPATION (IF APPLICABLE) IN THE FINANCING OPPORTUNITY; (4) SOUND OR SOUND (IF APPLICABLE) RECEIPT OR USE OF ANY REWARD, OR INABILITY TO RECEIVE OR USE ANY REWARD; (5) A CLAIM BY A THIRD PARTY THAT THE SUBMISSION, OR ANY SERVICES OR PRODUCTS DISCUSSED IN THE SUBMISSION, OR ANY MATERIAL OF ANY KIND PROVIDED BY IT, HIM OR HER (IF APPLICABLE), INFRINGES (EITHER DIRECTLY, CONTRIBUTORLY OR OTHERWISE), BAD OR VIOLATED THE INTELLECTUAL PROPERTY RIGHTS OF THIS THIRD PARTY; AND / OR (6) A THIRD PARTY CLAIM RELATING TO THE THIRD PARTY’S USE OF THE PARTICIPANT’S SUBMISSION. THE SPONSOR MAKES NO REPRESENTATIONS OR WARRANTIES REGARDING THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE INFORMATION PROVIDED TO THE PARTICIPANT IN CONNECTION WITH THE FUNDING OPPORTUNITY AND EXPRESSLY DISCLAIMS ANY WARRANTIES, EXPRESS OR IMPLIED OR IMPLIED. IN NO EVENT SHALL THE SPONSOR BE LIABLE FOR ANY DAMAGES (INCLUDING, WITHOUT LIMITATION, INCIDENTAL OR CONSEQUENTIAL DAMAGES, BODILY INJURY / DEATH, LOST PROFITS OR ANY OTHER DAMAGES) RESULTING FROM THE USE OF ANY INFORMATION PROVIDED. IN RELATION TO FINANCING.

]]>
https://vicvarney.com/official-rules-for-the-pain-management-funding-opportunity/feed/ 0
Sanara MedTech Inc. Announces Exclusive Partnership with Pixalere Healthcare Inc. to Advance Global Wound and Skin Care Strategy https://vicvarney.com/sanara-medtech-inc-announces-exclusive-partnership-with-pixalere-healthcare-inc-to-advance-global-wound-and-skin-care-strategy/ https://vicvarney.com/sanara-medtech-inc-announces-exclusive-partnership-with-pixalere-healthcare-inc-to-advance-global-wound-and-skin-care-strategy/#respond Fri, 04 Jun 2021 13:15:00 +0000 https://vicvarney.com/sanara-medtech-inc-announces-exclusive-partnership-with-pixalere-healthcare-inc-to-advance-global-wound-and-skin-care-strategy/ FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara”, the “Company”, “we”, “our” or “our”) (NASDAQ: SMTI), a supplier of surgical and chronic wound care products dedicated to improving patient outcomes, today announced an exclusive partnership with Pixalere Healthcare Inc. (“Pixalere”). Ron […]]]>

FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc.

Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara”, the “Company”, “we”, “our” or “our”) (NASDAQ: SMTI), a supplier of surgical and chronic wound care products dedicated to improving patient outcomes, today announced an exclusive partnership with Pixalere Healthcare Inc. (“Pixalere”).

Ron Nixon, Executive Chairman of Sanara, said, “Our goal at Sanara MedTech is to provide comprehensive wound and skin care solutions in all care settings. Our partnership with Pixalere is essential to achieving this goal by combining Pixalere’s technology, including decision support, documentation, and wound tracking analysis, with complementary Sanara solutions that provide virtual access to expert wound and skin physicians / clinicians, advanced diagnostics and wound care product order fulfillment. “

Overview of investments and partnerships
Sanara purchased Class A preferred shares of Pixalere convertible into 27.3% of the outstanding shares of Pixalere. Sanara will report its investment in Pixalere using the equity method. Sanara’s 27.3% share of Pixalere operations will be included in Sanara’s income statement as other income (or expense).

Concurrent with this investment, Sanara created Pixalere Healthcare USA, LLC (“Pixalere USA”) as a subsidiary of Sanara. Pixalere has granted Pixalere USA an exclusive royalty-free license to use the Pixalere software and platform in the United States. In exchange for the exclusive license, Pixalere USA issued a 27.3% stake in the capital of Pixalere.

Presentation of Pixalère
Pixalere is a cloud-based wound care software tool that empowers nurses, specialists and administrators to provide better bedside care. Currently, Pixalere serves and supports over 8,000 daily clinical users as they treat over 40,000 wound patients each year in Canada and other non-US markets. Pixalere currently offers the following solutions to its customers:

These capabilities are currently integrated with Sanara’s WounDerm platform to better serve the US wound care market.

Pixalere / WounDerm integration
Sanara’s partnership with Pixalere advances the company’s overall wound and skin care strategy by integrating key solutions that were developed by WounDerm with current Pixalere capabilities. This should allow Sanara’s technology to be paired with a proven, scalable model that provides bedside caregivers who are not specialized in wound care with more information and guidance than the current standard of care.

WounDerm features currently built into Pixalere include:

  • The WounDerm mobile app

  • Wound Care Plan Algorithms

  • Efficient revenue cycle workflows

  • Development of automated and modifiable progress notes

  • Wound assessment forms that interface with corresponding wound assessment data in electronic health record systems and provider practice management systems.

The partnership will use Pixalere’s experienced IT team to support any maintenance and customization requests that Pixalere USA will require.

Sanara and Pixalere plan to explore the use of the Precision Healing smart tablet and imager, Sanara’s proprietary product portfolio, and Sanara’s telehealth services in Pixalere’s current non-U.S. Markets including Canada, ‘South Africa, Australia and New Zealand.

About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets and distributes wound and skin care products to physicians, hospitals, clinics and to all post-acute care settings and seeks to offer wound care and virtual consultation in dermatology services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgically Activated Collagen® in the surgical markets as well as the following products in the wound care market: BIAKŌS ™ Antimicrobial Skin and Wound Cleanser, BIAKŌS ™ Antimicrobial Wound Gel, BIAKŌS ™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL ™ Hydrolyzed Collagen. Sanara is constantly on the lookout for long-term strategic partnerships with a focus on products that improve results at a lower overall cost. In addition, Sanara is actively seeking to expand in its six focus areas of wound and skin care for the acute, post-acute and surgical markets. Focus areas are Debridement, Biofilm Removal, Hydrolyzed Collagen, Advanced Biologics, Adjuncts for Negative Pressure Wound Treatment and Oxygen Delivery Systems segment of the health industry. For more information visit SanaraMedTech.com.

Information on forward-looking statements
Statements in this press release that are not historical facts are “forward-looking statements”, within the meaning and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “anticipate”, “believe”, “contemplate”, “pursue” “could”, “estimate”, “‘,”, “plan”, “seek”, “should”, “target”, “will” or “would”, or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include statements regarding the strategic partnership with Pixalere and the integration of Pixalere’s technology into Sanara’s product and service offerings, the extension of the strategic partnership with Pixalere to non-US markets, the development of new products. and the expansion of the Company’s activities as a telehealth and wound care business. These elements involve risks, contingencies and uncertainties such as the extent of demand for products, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to realize and d ” incorporate acquisitions, and other risks, contingencies and uncertainties detailed in filings with the SEC, which could cause actual operating results, performance or business plans or prospects of the Company differ materially from those expressed or implied by such statements.

All forward-looking statements speak only as of the date on which they are made, and the Company does not undertake to revise these statements to reflect future circumstances or the occurrence of unforeseen events, except as required by applicable laws. applicable securities.

Investor contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com

SOURCE: Sanara MedTech Inc.

See the source version on accesswire.com:
https://www.accesswire.com/650187/Sanara-MedTech-Inc-Announces-Exclusive-Partnership-with-Pixalere-Healthcare-Inc-to-Advance-its-Comprehensive-Wound-and-Skin-Care-Strategy

]]>
https://vicvarney.com/sanara-medtech-inc-announces-exclusive-partnership-with-pixalere-healthcare-inc-to-advance-global-wound-and-skin-care-strategy/feed/ 0